Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

M210B4 cells activated with anti-CD84 (clone 152-1D5)

ABSTRACT: M210B4 cells activated with anti-CD84 (clone 152-1D5)

PROVIDER: PRJNA419154 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

M210B4 cells activated with anti-CD84 (clone 152-1D5)

Project description:M210B4 cells activated with anti-CD84 (clone 152-1D5)

| PRJNA419154 | ENA

M210B4 cells activated with anti-CD84 (clone 152-1D5)

Project description:CD84 can be expressed on stromal cells in CLL, its target gene in these cells have yet to be identified. This experiment aimed at determining the CD84 regulated genes on stroma.

2018-11-28 | GSE107140 | GEO

Next Generation Sequencing Facilitates Quantitative Analysis of human multiple myeloma derived CD84 activated M-MDSCs or IgG (control) treated M-MDSCs

Project description:Purpose: Next-generation sequencing (NGS) has revolutionized systems-based analysis of cellular pathways. The goals of this study are to compare CD84 activated to control treated primary human M-MDSCs from multiple myeloma patients transcriptome profiling (RNA-seq) to understand the role of CD84 on these cells Methods: mRNA profiles from sorted M-MDSCs from patient bone marrow samples were generated by deep sequencing, in triplicate, using a bulk adaptation of the MARS-Seq protocol.

2021-05-25 | GSE164652 | GEO

Next Generation Sequencing Facilitates Quantitative Analysis of human multiple myeloma derived CD84 activated G-MDSCs or IgG (control) treated G-MDSCs

Project description:Purpose: Next-generation sequencing (NGS) has revolutionized systems-based analysis of cellular pathways. The goals of this study are to compare CD84 activated to control treated primary human G-MDSCs from multiple myeloma patients transcriptome profiling (RNA-seq) to understand the role of CD84 on these cells Methods: mRNA profiles from sorted G-MDSCs from patient bone marrow samples were generated by deep sequencing, in triplicate, using a bulk adaptation of the MARS-Seq protocol.

2021-05-25 | GSE164651 | GEO

Bulk RNA-seq of IVD-hMDSCs treated upon CD84 ligation

Project description:CD84 is a key marker of PMN-MDSCs in multiple mouse models and patients tumor samples. Increased CD84 expression levels were found in pathophysiological conditions associated with thrombo-inflammation

2024-08-21 | GSE272966 | GEO

Sapientia aquatica strain:SA-152 | isolate:SA-152

Project description:Sapientia aquatica strain:SA-152 | isolate:SA-152 Genome sequencing and assembly

| PRJNA526854 | ENA

Transcription profiling of mouse Th1 T cell clone and anergic Th1 T cell clone made anergic by plate-bound anti-CD3 antibody

Project description:compare gene expression profiles between normal and anergic T cells and identify upregulated genes in anergic T cells Experiment Overall Design: RNA from normal Th1 T cell clone and anergic Th1 T cell clone made anergic by plate-bound anti-CD3 antibody were isolated and amplified for microarray analysis

2008-06-14 | E-GEOD-5960 | biostudies-arrayexpress

SAGE and MPSS libraries from activated CD4+ T cell clone 29

Project description:SAGE and MPSS libraries were produced from the same RNA sample extracted from an activated CD4+ T cell clone in order to compare the ability of these techniques to indentify the full range of genes expressed in a single cell type. Keywords: Technical comparison of tag-based technologies SAGE and MPSS

2007-08-02 | GSE8612 | GEO

Bradyrhizobium ottawaense strain:USDA 152 | isolate:USDA 152

Project description:Bradyrhizobium ottawaense USDA 152 genome sequencing

| PRJNA1115783 | ENA

A Study of Combination of Anti-PD1 Antibody-activated TILs and Chemotherapy in Colorectal Cancer

Project description:This study was a phase I/II trial initiated by the investigator to evaluate the safety and tolerability of anti-programmed cell death protein 1 (anti-PD1) antibody-activated autologous tumor-infiltrating lymphocytes (TILs) combined with adjuvant chemotherapy in participants with stage III colon cancer. Twenty participants were enrolled and anti-PD1 antibody-activated TILs was infused into participants after the final of adjuvant chemotherapy to assess the safety and 3-year disease-free survival.

| 2302069 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data